ARTICLE | Clinical News
Dasotraline: Phase II/III data
September 26, 2016 7:00 AM UTC
Sumitomo Dainippon’s Sunovion Pharmaceuticals Inc. subsidiary reported top-line data from the double-blind, U.S. Phase II/III SEP360-202 trial in 342 ADHD patients ages 6-12 showing that once-daily 4 ...